What is the average vitreous elimination half-life of ranibizumab (Lucentis) in patients with neovascular age-related macular degeneration receiving 0.5 mg intravitreal injections?

The average vitreous elimination half-life of ranibizumab (Lucentis) in patients with neovascular age-related macular degeneration receiving 0.5 mg intravitreal injections is approximately 9 days, based on population pharmacokinetic analysis and disappearance of ranibizumab from serum.